FDA Will Probe Diabetes Drug Safety Risk Report

Law360, New York (March 14, 2013, 4:48 PM EDT) -- The U.S. Food and Drug Administration said Thursday that it would investigate a new report claiming a class of diabetes drugs, including ones manufactured by drug giants such as Merck & Co. Inc., Bristol-Myers Squibb Co. and AstraZeneca PLC, may cause precancerous changes in the pancreas.

The FDA said that it would evaluate unpublished new findings by a group of academic researchers that suggest a class of Type 2 diabetes drugs called incretin mimetics may lead to an increased risk of pancreatitis and precancerous cellular changes...
To view the full article, register now.